Evidence map›Paper›PMID 42474610›Full record

ArticleAnnals of nuclear medicine2026

Development of a

Kerim Şeker, Mukaddes Yılmaz, Eda Erdiş, Zekiye Hasbek

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kerim ŞekerDepartment of Nuclear Medicine, Faculty of Medicine, Sivas Cumhuriyet University, Sivas, Türkiye. kerimseker@cumhuriyet.edu.tr.ORCID http://orcid.org/0000-0003-1683-1776
Mukaddes YılmazDepartment of Medical Oncology, Faculty of Medicine, Sivas Cumhuriyet University, Sivas, Türkiye.
Eda ErdişDepartment of Radiation Oncology, Faculty of Medicine, Sivas Cumhuriyet University, Sivas, Türkiye.
Zekiye HasbekDepartment of Nuclear Medicine, Faculty of Medicine, Sivas Cumhuriyet University, Sivas, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePrognosis in small cell lung cancer (SCLC) remains poorly predicted by conventional staging and metabolic parameters. This study aimed to develop a positron emission tomography/computed tomography (PET/CT) based Radiomic Risk Score (Rad-Score), evaluate its independent prognostic value for overall survival (OS), and assess the clinical utility of an integrated model using Decision Curve Analysis (DCA). MATERIALS AND

methods143 SCLC patients (120 male, 23 female) who underwent pre-treatment staging

resultsMedian OS was 10.8 months (95% CI: 8.2-13.3), with a mortality rate of 83.9%. Multivariable analysis identified the Radiomic Risk Group (HR: 2.12; 95% CI: 1.33-3.40; p = 0.002) and Curative CRT (HR: 0.17; 95% CI: 0.06-0.48; p < 0.001) as independent prognostic factors. The C-index improved from 0.657 to 0.688 (p = 0.018) and to 0.701 with Rad-Score integration (p = 0.0017). DCA demonstrated superior net benefit at high threshold probabilities (≥ 65%).

conclusionThe

Indexed as

18F-FDG PET/CTDecision curve analysisLASSORad-scoreSmall cell lung cancerSurvival

Identifiers

PMID42474610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.